摘要
目的:探讨阿帕替尼联合替吉奥对复发转移食管癌进行二线治疗的疗效及毒副作用。方法:收集2015年6月至2016年12月于开封市中心医院肿瘤科诊治的24例复发转移食管癌患者,分为观察组和对照组。观察组10例口服阿帕替尼联合替吉奥化疗,口服阿帕替尼500 mg/d,替吉奥根据体表面积给药治疗1~14 d,28 d为1个周期。对照组14例用常规替吉奥治疗。结果:2个周期化疗后评价疗效:CR 0例,PR 5例,SD 3例,PD 2例;OR为50%(5/10),DCR为80%(8/10)。治疗前20个靶病灶基线直径和为71.5 cm,2个周期治疗后靶病灶直径和为40.5 cm,较基线水平缩小达43.36%。6例患者完成4个周期联合化疗后,疗效评价有效或稳定患者继续单药口服阿帕替尼维持治疗,PFS最长达9个月,最短6个月。未观察到与药物相关的严重毒副反应。结论:阿帕替尼联合替吉奥对复发转移食管癌二线治疗疗效较好,安全性、耐受性可。
Objective： To explore efficacy of apatinib plus S- 1 to treat the patients with recurrent and metastatic esophageal cancer as 2^nd line therapy and its toxic and side effects. Methods： Twenty-four patients with recurrent and metastatic esophageal cancer who diagnosed and remedied in Department of Oncology, the Central Hospital of Kaifeng during June 2015 to December 2016 were collected. Them were divided into Observation and Control groups. Ten patients in the Observation group took orally apatinib plus S-1 as chemotherapy, apatinib was orally tak- en in 500 mg/d and S-1 taken according to body surface area for 1 to 14 days. Twenty eight days were as one cycle. Fourteen patients in the Control group were treated with routine S-1. Results： After two cycles, efficacy of the che- motherapy was evaluated as CR 0 case; PR 5 cases; SD 3 cases and PD 2 cases. ORR was 50% （5/10） and DCR was 80% （8/10）. Before the chemotherapy, baseline diameter sum of 20 target lesions was 71.5 cm, diameter sum of the 20 target lesions became 40.5 cm after 2 cycles of the chemotherapy, and the diameter sum decreased by 43.36% compared with the baseline diameter sum. After six patients completed 4 cycles of the combination chemotherapy, the patients whose efficacy evaluation were effective or stable continued to take orally apatinib alone for mainte- nance therapy, the longest PFS of the patients was 9 months and their shortest PFS 6 months. Sever drug-related tox- ic and side effects didn＇t be observed. Conclusion： Efficacy of apatinib plus S-1 to treat the patients with recurrent and metastatic esophageal cancer as 2^nd line therapy might be better, and its safety and tolerability could be accept- able.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
北大核心
2017年第11期1315-1319,共5页
Chinese Journal of Cancer Biotherapy
关键词
阿帕替尼
替吉奥
食管癌
二线治疗
apatinib
S-1
esophageal cancer
the 2^nd line therapy
